Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 16, 2011

Standard of Care, Overseas Opportunities Top Strategies Firms Use to Overcome MDX Reimbursement Issues

  • Exactly half of respondents to a GEN poll say their companies are working to gain provider acceptance and reimbursement for personalized medicine by pursuing standard-of-care status for their molecular diagnostics. Another third (33.3%) are concentrating their efforts on developing diagnostics for markets outside the U.S., while 16.7% said they are forming partnerships with the pharmaceutical industry. Steven Burrill, CEO of Burrill & Company, has likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »